Anti-Human IL-21 (Intermediate Domain)

Anti-Human IL-21 (Intermediate Domain)

Product No.: I-352

[product_table name="All Top" skus="I-352"]

- -
- -
Target
IL-21
Product Type
Polyclonal Antibody
Alternate Names
Interleukin-21, Za11
Applications
IHC FFPE
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Rabbit
Immunogen
PN:I-353
Product Concentration
0.5 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Rabbit Anti-Human Interleukin-21 (IL-21) recognizes an epitope in the intermediate domain of Human IL-21. This polyclonal antibody was purified using affinity chromatography.
Background
Interleukin 21 (IL-21) is a T cell-derived pleiotropic cytokine that has potent regulatory effects on cells of the immune system, including natural killer (NK) cells and cytotoxic T cells that can destroy virally infected or cancerous cells.1,2 This cytokine induces cell division/proliferation in its target cells. IL-21 elicits its effects on immune cells by interacting with a cell surface receptor known as the interleukin 21 receptor, IL-21R, which is expressed in bone marrow cells and various lymphocytes. IL-21 is closely related to IL-2 and IL-153 and is a key factor in the transition between innate and adaptive immune responses.4 The critical role of IL21 in promoting humoral immune responses makes it an important focus of potential therapeutic interventions in conditions characterised by overproduction of pathogenic autoantibodies.5
PubMed
NCBI Gene Bank ID

References & Citations

1. Foster D et al. (2000) Nature 408: 57
2. Clegg CH et al. (2002) J. Leukoc. Biol. 72: 856
3. Leonard WJ.et al. (2002) Science 298: 1630
4. Joannopoulos K.et al. (2003) J. Immunol. 171: 608
5. Lipsky PE. et al. (2008) Ann Rheum. Dis. 3: 83
IHC FFPE
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.